The Use of Human Biological Materials in the Development of Biomedical Products: Hearing Before the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, House of Representatives, Ninety-ninth Congress, First Session, October 29, 1985U.S. Government Printing Office, 1986 - 278 sider |
Inni boken
Resultat 1-5 av 28
Side 6
... doctor ? Is it the hospital or the university ? Or is it perhaps really those future patients who might either get ... doctors , scientists , and universities in litigation be- cause of the threat , however tenuous , from their research ...
... doctor ? Is it the hospital or the university ? Or is it perhaps really those future patients who might either get ... doctors , scientists , and universities in litigation be- cause of the threat , however tenuous , from their research ...
Side 18
... Doctor of Medicine , or Bachelor of Laws has in recent years been more prestigious among youth in our society than to be a chemist or engineer , yet these latter professionals produce the products and services on which industry is based ...
... Doctor of Medicine , or Bachelor of Laws has in recent years been more prestigious among youth in our society than to be a chemist or engineer , yet these latter professionals produce the products and services on which industry is based ...
Side 35
... doctor ? Is it the hospital or university ? Or is it perhaps really those future patients who might either get the disease , and / or who might be saved from ravages of the disease , because of the " information " derived from a ...
... doctor ? Is it the hospital or university ? Or is it perhaps really those future patients who might either get the disease , and / or who might be saved from ravages of the disease , because of the " information " derived from a ...
Side 36
... doctors , scientists and universities in litigation because of the threat , however tenuous , from their research to a therapeutic process or product is clear . The threat of litigation to universities for therapies that emerge from ...
... doctors , scientists and universities in litigation because of the threat , however tenuous , from their research to a therapeutic process or product is clear . The threat of litigation to universities for therapies that emerge from ...
Side 60
... Doctor ? Dr. RATHMANN . Well , again , we probably have a slight difference here . It seems to me that if there is a product , then the risk of not permitting some type of exclusivity in a relationship with a compa- ny would be a very ...
... Doctor ? Dr. RATHMANN . Well , again , we probably have a slight difference here . It seems to me that if there is a product , then the risk of not permitting some type of exclusivity in a relationship with a compa- ny would be a very ...
Andre utgaver - Vis alle
Vanlige uttrykk og setninger
academic activity applied research appropriate approved basic research BELMONT REPORT benefits biotechnology BLAKE blood body cancer cell line Chairman commercial conducted conflicts of interest consent form Department of Health discovery disease doctor donation ethical example Federal fetus funding Genentech genetic engineering gift Government human biological materials hybridomas individual industry informed consent Institutes of Health Institutional Review Board investigator involving human subjects issues LEVINE licensing lymphokines MCCARTHY minimal risk monoclonal antibodies MOORE Murray NATIONAL RESEARCH ACT obtained October 29 organ organ donation PACKARD participation particular patient Patrick Ewing physician pituitaries potential problem procedures profit programs PROTECTION OF HUMAN question RATHMANN RAUB regulations REIMERS relationship reporting research involving human research subjects scientific scientists Secretary specific statement subcommittee subpart Thank tion tissue TRAFICANT unique university-industry vitro fertilization VOLKMER
Populære avsnitt
Side 174 - Act, or other public benefit or service programs; (ii) procedures for obtaining benefits or services under those programs; (Hi) possible changes in or alternatives to those programs or procedures; or (iv) possible changes in methods or levels of payment for benefits or services under those programs; and (2) The research could not practicably be carried out without the waiver or alteration. (d) An IRB may approve a consent procedure which does not include, or which alters, some or all of the elements...
Side 171 - IRB shall be sufficiently qualified through the experience and expertise of its members, and the diversity of the members, including consideration of race, gender, and cultural backgrounds and sensitivity to such issues as community attitudes, to promote respect for its advice and counsel in safeguarding the rights and welfare of human subjects.
Side 172 - Risks to subjects are minimized: (i) by using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to risk, and (ii) whenever appropriate, by using procedures already being performed on the subjects for diagnostic or treatment purposes. (2) Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result.
Side 168 - Research conducted in established or commonly accepted educational settings, involving normal educational practices, such as (i) research on regular and special education instructional strategies, or (ii) research on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods. (2) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement...
Side 170 - Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered In daily life or during the performance of routine physical or psychological examinations or tests.
Side 169 - Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available, or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
Side 172 - Expedited review procedures for certain kinds of research involving no more than minimal risk, and for minor changes in approved research.
Side 174 - That the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context.
Side 169 - Legally authorized representative means an individual or judicial or other body authorized under applicable law to consent on behalf of a prospective subject to the subject's participation in the procedure(s) involved in the research.
Side 181 - Where parental permission is to be obtained, the IRB may find that the permission of one parent is sufficient for research to be conducted under § 46.404 or § 46.405. Where research is covered by § § 46.406 and 46.407 and permission is to be obtained from parents, both parents must give their permission unless one parent is deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal responsibility for the care and custody of the child.